Less Ads, More Data, More Tools Register for FREE

Pin to quick picksReneuron Regulatory News (RENE)

  • This share is currently suspended. It was suspended at a price of 3.275

Share Price Information for Reneuron (RENE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.275
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.00 (0.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 3.275
RENE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Shares notification

31 Jan 2007 09:37

ReNeuron Group plc31 January 2007 TR-1: NOTIFICATION OF MAJOR INTERESTS IN SHARES 1. Identity of the issuer or the underlying issuer RENEURON GROUP PLCof existing shares to which voting rights are attached 2. Reason for the notification (please tick the appropriate box or boxes)An acquisition or disposal of voting rights X An acquisition or disposal of financial instruments which may result in theacquisition of shares already issued to which rioting rights are attached An event changing the breakdown of voting rights 3. Full name of person(s) subject to the SAAD INVESTMENTS COMPANY LIMITED notification obligation4. Full name of shareholder(s) (if different from 3.) Vidacos Nominees Ltd (Citigroup Global AWAL)5. Date of the transaction and date on which the Not specified. threshold is crossed or reached6. Date on which issuer notified 30 January 2007 A: Voting rights attached to sharesClass/type Situation Resulting situation after the triggering transaction vi of shares previous to the Triggering if possible transactionusing the ISIN Number of Number Number of Number of voting rights % of voting rightsCODE Shares shares ix of Voting Rights Direct Direct Indirect Direct Indirect Ordinary Shares Not Not 18,950,000 18,950,000 0 15.988% 0 specified specified B: Financial InstrumentsResulting situation after the triggering transactionType of financial Expiration Exercise/Conversion Number of voting rights % of voting date Period/Date that may be acquired if rightsinstrument the instrument is - exercised/converted N/A - - - - Total (A+B)Number of voting rights % of voting rights 18,950,000 15.988% 9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectivelyheld, if applicable None specified. Proxy Voting: 10. Name of the proxy holder: N/A 11. Number of voting rights proxy holder will cease to hold: N/A12. Date on which proxy holder will cease to hold voting N/Arights: 13. Additional information: Recent acquisition. 14. Contact name: Michael Hunt, CEO15. Contact telephone number: 01483 302560 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
7th Oct 20227:00 amRNSPositive Exosome data presented at US conference
22nd Sep 20227:00 amRNSReNeuron to present new data at Exosome conference
14th Sep 20227:00 amRNSDirectorate and Executive Changes
9th Sep 202210:58 amRNSResult of AGM
2nd Sep 202211:01 amRNSDirector/PDMR Shareholding
1st Sep 20227:00 amRNSBlock Listing Review and Total Voting Rights
15th Aug 20223:25 pmRNSPosting of AR & Accounts & Notice of AGM
1st Aug 20227:00 amRNSDirectorate Change
15th Jul 20227:00 amRNSGrant of Options
14th Jul 20227:00 amRNSShare Purchase by a Director
13th Jul 20227:00 amRNSShare Purchase by a Director
4th Jul 20227:00 amRNSPreliminary Results
1st Jul 20227:00 amRNSFosun Tech Transfer and Supply Agreement update
20th Jun 20227:00 amRNSNotice of Results
3rd May 20227:00 amRNSReNeuron to present at ISCT 2022 in San Francisco
25th Apr 20227:00 amRNSDirector Declaration
23rd Mar 20227:00 amRNSHolding(s) in Company
22nd Mar 20227:01 amRNSDirectorate Changes
22nd Mar 20227:00 amRNSAppointment of Nominated Adviser and Joint Broker
8th Mar 20227:00 amRNSBlock Listing Review and Total Voting Rights
7th Mar 20224:00 pmRNSHolding(s) in Company
2nd Mar 20227:00 amRNSDirector exit arrangements
11th Feb 20224:41 pmRNSSecond Price Monitoring Extn
11th Feb 20224:36 pmRNSPrice Monitoring Extension
11th Feb 20222:38 pmRNSHolding(s) in Company
11th Feb 20227:00 amRNSDirector Change
10th Feb 20229:49 amRNSHolding(s) in Company
9th Feb 202211:59 amRNSHolding(s) in Company
4th Feb 20225:17 pmRNSHolding(s) in Company
28th Jan 20227:00 amRNSInvestor Presentation
26th Jan 20222:06 pmRNSSecond Price Monitoring Extn
26th Jan 20222:01 pmRNSPrice Monitoring Extension
18th Jan 20224:35 pmRNSPrice Monitoring Extension
18th Jan 20222:06 pmRNSSecond Price Monitoring Extn
18th Jan 20222:00 pmRNSPrice Monitoring Extension
18th Jan 202211:05 amRNSSecond Price Monitoring Extn
18th Jan 202211:00 amRNSPrice Monitoring Extension
18th Jan 20229:05 amRNSSecond Price Monitoring Extn
18th Jan 20229:00 amRNSPrice Monitoring Extension
18th Jan 20227:00 amRNSStrategic update
13th Jan 20227:00 amRNSAdditional agreement with Fosun Pharma for CTX
11th Jan 20227:00 amRNSNew Senior Appointment
17th Dec 20212:00 pmRNSDirector Declaration
30th Nov 20217:00 amRNSInterim Results
19th Nov 20217:00 amRNSCTX-iPSC platform data shows commerical potential
18th Nov 20217:00 amRNSNotice of Results
1st Nov 20217:00 amRNSTotal Voting Rights
26th Oct 20213:09 pmRNSDirector exit arrangements
26th Oct 20217:00 amRNSCollaboration agreement with UCL
21st Oct 20217:00 amRNSDirector Share Purchase

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.